Sutent Renal Cell Carcinoma

ASCO: Two-Year Survival Seen With Sutent In Kidney Cancer
Http://www.medpagetoday.com Robert A. Figlin, M.D., City of Hope, Duarte, Calif. CHICAGO -- In patients with treatment-naive advanced renal cell carcinoma, treatment with sunitinib (Sutent) more than doubled progression-free survival compared with interferon alfa. ... View Video

Prior Authorization Criteria Drug: Sutent® (sunitinib Malate)
Dosage and Administration: The recommended dose of Sutent for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma is one 50 mg oral dose taken daily, on a schedule of 4 weeks on treatment ... Access Full Source

Sutent Covered Medication Sunitinib (Sutent What It Does And ...
Sunitinib (Sutent ) What it does and Renal cell carcinoma (RCC) is the most common form of kidney cancer representing approximately 90% of cases. Approximately 30% of patients present with metastatic disease, 25% with locally advanced disease and 45% with ... Read Full Source

Drug: Sunitinib (Sutent ®)
Drug: Sunitinib (Sutent ®) Sponsor: Pfizer, Inc. Proposed Indication: Unresectable pancreatic neuroendocrine tumors (PNET) April 12, 2011 Oncology Drugs Advisory Committee. 2 Sunitinib PNET sNDA review Team GIST and advanced renal cell carcinoma ... Read Here

Business Intelligence Analysis: Focus On Renal Cell Carcinoma
Renal Cell Carcinoma Sutent Efficacy: In a trial of 750 patients with previously untreated, metastatic RCC in a multicenter, randomized, Phase III trial to receive either repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed ... Read More

SUTENT. SUTENT
1.2 Advanced Renal Cell Carcinoma (RCC) SUTENT is indicated for the treatment of advanced renal cell carcinoma. 1.3 . Advanced Pancreatic Neuroendocrine Tumors (pNET) SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors ... Get Doc

Pharmacy Medical Necessity Guidelines: Sutent (sunitinib)
Sutent (sunitinib) is a kinase inhibitor for the treatment of: Advanced Renal Cell Carcinoma (RCC) Progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease ... Fetch Content

Neuroendocrine Tumor - Wikipedia, The Free Encyclopedia
Neuroendocrine cancer (NEC) (synonymous with islet cell carcinoma) is more aggressive. Up to 60% of PanNETs are Targeted therapy with everolimus (Afinitor) and sunitinib (Sutent) is approved by the FDA in unresectable, locally Renal cell carcinoma; Endometrioid tumor; Renal oncocytoma; ... Read Article

Sunitinib - Wikipedia, La Enciclopedia Libre
Fecal (61%) y renal (16%) Datos clínicos; Estado legal: Modelo de la molécula de sunitibib en esferas y barras. El sunitinib (comercializado como Sutent, y previamente conocido como SU11248) El sunitinib es el tratamiento estándar de primera línea del carcinoma de celular renales ... Read Article

RENAL CELL CARCINOMA TREATMENT REGIMENS (Part 1 Of 2)
RENAL CELL CARCINOMA TREATMENT REGIMENS (Part 1 of 2) Sutent [package insert]. New York, NY: Pfizer Labs; 2011. 3. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of suni-tinib for metastatic renal-cell carcinoma: an expanded-access ... Retrieve Full Source

Sunitinib In Advanced Renal Cell Carcinoma: Clinical Evidence
Sunitinib in Advanced Renal Cell Carcinoma: Clinical Evidence Joaquim Bellmunt* Solid Tumor Oncology (GU & GI), Medical Oncology Service, Hospital Del Mar, Paseo Maritimo 25-29, Barcelona 08003, Spain ... Fetch Here

Sutent (Sunitinib)
Sutent (Sunitinib) Sutent (sunitinib) is used for the treatment of gastrointestinal stromal tumor (GIST) in patients intolerant or with disease progression on ... Access Document

Sunitinib (Sutent®) - National Health Service
Inhibitors > Sunitinib (Sutent®) Sunitinib (Sutent®) This information is about sunitinib, which is also known as Sutent®. It may be used to treat people with a type of kidney cancer called renal cell carcinoma (RCC) and a rare type of cancer called gastrointestinal stromal tumours (GIST). ... Get Document

Sunitinib (for Metastatic Renal Cell Carcinoma)
Highlights of Recommendation: Sunitinib (Sutent) is a new drug treatment for patients with Metastatic Renal Cell Carcinoma (MRCC). MRCC is kidney cancer that has spread to other ... Access Document

Sunitinib And Axitinib In Renal Cell Carcinoma
Sunitinib and Axitinib in Renal Cell Carcinoma Robert J. Motzer Abstract Sunitinib and axitinib are two oral, small-molecule agents that emerged ... Read Document

Renal Cell Carcinoma (RCC) U.S. Fact Sheet - Pfizer
Renal cell carcinoma (RCC), o In addition, increased levels of PDGF may be associated with tumor progression in renal cell carcinomas. 8 The mammalian target of rapamycin (mTOR) 14 SUTENT (sunitinib malate) Prescribing Information. ... Return Document

Sunitinib (Handelsname: Sutent ... Read Article

SUTENT (sunitinib Malate) Capsules
SUTENT® (sunitinib malate) Capsules Mace L. Rothenberg, MD Senior VP, Clinical Development and Medical Affairs, Pfizer Inc – Advanced renal cell carcinoma (RCC) Gastrointestinal stromal tumor (GIST) after disease progression on or 5 ... Read Document

Sutent - European Medicines Agency
For GIST and metastatic renal cell carcinoma, Sutent is given in six-week cycles, at a dose of 50 mg once a day for four weeks, followed by a two-week ‘rest period’. ... Read Here

Sutent Renal Cell Carcinoma Analysis And Forecasts ... - YouTube
GlobalDatas pharmaceuticals report, Sutent (Renal Cell Carcinoma) Analysis and Forecasts to 2022 provides Sutent sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of ... View Video

Sutent. Prior Authorization Criteria
Sutent . Prior Authorization Group: Sutent. Drug Names: Sutent. Covered Uses: Clinically documented renal cell carcinoma, Or Clinically documented gastrointestinal stromal tumor (GIST) with disease progression and/or intolerance while ... Read Here

Pazopanib Versus Sunitinib In Metastatic Renal-Cell Carcinoma
Pazopanib vs. Sunitinib in Renal-Cell Carcinoma n engl j med 369;8 nejm.org august 22, 2013 723 R enal-cell carcinoma is the most common kidney cancer.1 Up to 30% of pa- ... Retrieve Full Source

Celldex Presents Varlilumab Mechanism Data At SITC Annual Meeting 2015
-- Preclinical data suggest cancers vary in sensitivity to mechanisms of CD27 immune modulation -- ... Read News

Metastatic Lung Cancer - Metastatic Cancer To The Lungs
A persistent cough; Coughing up blood (hemoptysis) or bloody sputum; Pain in the chest, shoulder, and back; Shortness of breath; A pleural effusion; With metastatic lung cancer, patients often have symptoms related to the primary cancer in addition to lung symptoms. ... Read Article

The Use Of Sunitinib In renal cell carcinoma: Where Are We Now?
The use of sunitinib in renal cell carcinoma: where are we now? Expert Rev. Anticancer Ther. 14(9), 983–999 (2014) Anna M Czarnecka1, Cezary Szczylik1 and ... Doc Retrieval

Health Alliance: Sutent (sunitinib)
Health Alliance: Sutent Advanced renal cell carcinoma (RCC)1-3 Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate1-3 Progressive, well-differentiated pancreatic neuroendocrine tumors (PNETs) in patients with unresectable locally ... Read Content

SUTENT® (sunitinib Malate) Capsules Fact Sheet
SUTENT® (sunitinib malate) capsules Fact Sheet PRODUCT DESCRIPTION SUTENT (sunitinib malate INDICATIONS SUTENT is an oral multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor ... Access Document

Renal Cell Carcinoma - Causes, Symptoms, And Treatment
Renal cell carcinoma is the most common type of kidney cancer, accounting for up to 90% of cases of the disease. In renal cell carcinoma, malignant cells are believed to arise from the tubules of the kidney. Sutent; Nexavar; Avastin; Torisel; ... Read Article